Management of locally advanced pancreatic cancer: Results of an international survey of current practice Journal Article


Authors: Reames, B. N.; Blair, A. B.; Krell, R. W.; Groot, V. P.; Gemenetzis, G.; Padussis, J. C.; Thayer, S. P.; Falconi, M.; Wolfgang, C. L.; Weiss, M. J.; Are, C.; He, J.
Article Title: Management of locally advanced pancreatic cancer: Results of an international survey of current practice
Abstract: Objective: The aim of this study was to investigate surgeon preferences for the management of patients with locally advanced pancreatic cancer (LAPC). Background: Select patients with LAPC may become candidates for curative resection following neoadjuvant therapy, and recent reports of survival are encouraging. Yet the optimal management approach remains unclear. Methods: An extensive electronic survey was systematically distributed by email to an international cohort of pancreas surgeons. Data collected included practice characteristics, management preferences, attitudes regarding contraindications to surgery, and 6 clinical vignettes of patients that ultimately received a margin negative resection (with detailed videos of post-neoadjuvant imaging) to assess propensity for surgical exploration if resection status is not known. Results: A total of 153 eligible responses were received from 4 continents. Median duration of practice is 12 years (interquartile range 6-20) and 77% work in a university setting. Most surgeons (86%) are considered high volume (>10 resections/yr), 33% offer a minimally-invasive approach, and 50% offer arterial resections in select patients. Most (72%) always recommend neoadjuvant chemotherapy, and 65% prefer FOLFIRINOX. Preferences for the duration of chemotherapy varied widely: 39% prefer >= 2 months, 43% prefer >= 4 months, and 11% prefer >= 6 months. Forty-one percent frequently recommend neoadjuvant radiotherapy, and 53% prefer 5 to 6 weeks of chemoradiation. The proportion of surgeons favoring exploration following neoadjuvant varied extensively across 5 vignettes of LAPC, from 14% to 53%. In a vignette of oligometastatic liver metastases, 31% would offer exploration if a favorable therapy response is observed. Conclusions: In an international cohort of pancreas surgeons, there is substantial variation in management preferences, perceived contraindications to surgery, and the propensity to consider exploration in LAPC. These results emphasize the importance of a robust and nuanced multidisciplinary discussion for each patient, and suggest an evolving concept of "resectability."
Keywords: survival; gemcitabine; neoadjuvant therapy; chemotherapy; pancreas; hospital; resection; volume; multidisciplinary management; resectability; pancreas surgery; operative mortality; survey research; cancer; folfirinox; locally advanced pancreas cancer; head adenocarcinoma
Journal Title: Annals of Surgery
Volume: 273
Issue: 6
ISSN: 0003-4932
Publisher: Lippincott Williams & Wilkins  
Date Published: 2021-06-01
Start Page: 1173
End Page: 1181
Language: English
ACCESSION: WOS:000662304000041
DOI: 10.1097/sla.0000000000003568
PROVIDER: wos
PUBMED: 31449138
Notes: Article; Proceedings Paper -- 55th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2019 -- Chicago, IL -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Wallace Krell
    5 Krell